vs
Side-by-side financial comparison of LivaNova PLC (LIVN) and PROSPERITY BANCSHARES INC (PB). Click either name above to swap in a different company.
PROSPERITY BANCSHARES INC is the larger business by last-quarter revenue ($367.6M vs $360.9M, roughly 1.0× LivaNova PLC). PROSPERITY BANCSHARES INC runs the higher net margin — 31.6% vs 8.6%, a 23.1% gap on every dollar of revenue. Over the past eight quarters, PROSPERITY BANCSHARES INC's revenue compounded faster (19.2% CAGR vs 10.6%).
LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
Prosperity Bancshares, Inc. is a bank holding company headquartered in Houston, Texas with operations in Texas and central Oklahoma. As of December 31, 2019, the company operated 285 branches: 65 in the Houston area, including The Woodlands, Texas; 30 in South Texas, including Corpus Christi, Texas and Victoria, Texas; 75 in the Dallas–Fort Worth metroplex; 22 in East Texas; 29 in Central Texas, including Austin, Texas and San Antonio; 34 in West Texas, including Lubbock, Texas, Midland–Odess...
LIVN vs PB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $360.9M | $367.6M |
| Net Profit | $30.9M | $116.3M |
| Gross Margin | 65.2% | — |
| Operating Margin | 11.8% | — |
| Net Margin | 8.6% | 31.6% |
| Revenue YoY | 12.1% | — |
| Net Profit YoY | -44.7% | -10.7% |
| EPS (diluted) | $0.57 | $1.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $367.6M | ||
| Q4 25 | $360.9M | $275.0M | ||
| Q3 25 | $357.8M | $273.4M | ||
| Q2 25 | $352.5M | $267.7M | ||
| Q1 25 | $316.9M | $265.4M | ||
| Q4 24 | $321.8M | $267.8M | ||
| Q3 24 | $318.1M | $261.7M | ||
| Q2 24 | $318.6M | $258.8M |
| Q1 26 | — | $116.3M | ||
| Q4 25 | $30.9M | $139.9M | ||
| Q3 25 | $26.8M | $137.6M | ||
| Q2 25 | $27.2M | $135.2M | ||
| Q1 25 | $-327.3M | $130.2M | ||
| Q4 24 | $55.9M | $130.1M | ||
| Q3 24 | $33.0M | $127.3M | ||
| Q2 24 | $16.3M | $111.6M |
| Q1 26 | — | — | ||
| Q4 25 | 65.2% | — | ||
| Q3 25 | 68.4% | — | ||
| Q2 25 | 67.8% | — | ||
| Q1 25 | 69.7% | — | ||
| Q4 24 | 68.2% | — | ||
| Q3 24 | 70.8% | — | ||
| Q2 24 | 68.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 65.1% | ||
| Q3 25 | 15.1% | 64.4% | ||
| Q2 25 | 15.4% | 64.3% | ||
| Q1 25 | 15.3% | 62.7% | ||
| Q4 24 | 11.5% | 62.0% | ||
| Q3 24 | 11.2% | 62.1% | ||
| Q2 24 | 12.6% | 55.2% |
| Q1 26 | — | 31.6% | ||
| Q4 25 | 8.6% | 50.9% | ||
| Q3 25 | 7.5% | 50.3% | ||
| Q2 25 | 7.7% | 50.5% | ||
| Q1 25 | -103.3% | 49.1% | ||
| Q4 24 | 17.4% | 48.6% | ||
| Q3 24 | 10.4% | 48.6% | ||
| Q2 24 | 5.1% | 43.1% |
| Q1 26 | — | $1.16 | ||
| Q4 25 | $0.57 | $1.48 | ||
| Q3 25 | $0.49 | $1.45 | ||
| Q2 25 | $0.50 | $1.42 | ||
| Q1 25 | $-6.01 | $1.37 | ||
| Q4 24 | $1.04 | $1.36 | ||
| Q3 24 | $0.60 | $1.34 | ||
| Q2 24 | $0.30 | $1.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $635.6M | — |
| Total DebtLower is stronger | $376.1M | — |
| Stockholders' EquityBook value | $1.2B | $8.2B |
| Total Assets | $2.6B | $43.6B |
| Debt / EquityLower = less leverage | 0.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $635.6M | — | ||
| Q3 25 | $646.1M | — | ||
| Q2 25 | $593.6M | — | ||
| Q1 25 | $738.4M | — | ||
| Q4 24 | $428.9M | — | ||
| Q3 24 | $346.4M | — | ||
| Q2 24 | $329.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | $376.1M | — | ||
| Q3 25 | $434.5M | — | ||
| Q2 25 | $430.6M | — | ||
| Q1 25 | $628.2M | — | ||
| Q4 24 | $627.0M | — | ||
| Q3 24 | $625.5M | — | ||
| Q2 24 | $624.5M | — |
| Q1 26 | — | $8.2B | ||
| Q4 25 | $1.2B | $7.6B | ||
| Q3 25 | $1.2B | $7.7B | ||
| Q2 25 | $1.1B | $7.6B | ||
| Q1 25 | $1.0B | $7.5B | ||
| Q4 24 | $1.3B | $7.4B | ||
| Q3 24 | $1.3B | $7.4B | ||
| Q2 24 | $1.2B | $7.3B |
| Q1 26 | — | $43.6B | ||
| Q4 25 | $2.6B | $38.5B | ||
| Q3 25 | $2.6B | $38.3B | ||
| Q2 25 | $2.5B | $38.4B | ||
| Q1 25 | $2.6B | $38.8B | ||
| Q4 24 | $2.5B | $39.6B | ||
| Q3 24 | $2.5B | $40.1B | ||
| Q2 24 | $2.5B | $39.8B |
| Q1 26 | — | — | ||
| Q4 25 | 0.31× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.50× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $82.4M | — |
| Free Cash FlowOCF − Capex | $50.2M | — |
| FCF MarginFCF / Revenue | 13.9% | — |
| Capex IntensityCapex / Revenue | 8.9% | — |
| Cash ConversionOCF / Net Profit | 2.67× | — |
| TTM Free Cash FlowTrailing 4 quarters | $173.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $82.4M | $78.3M | ||
| Q3 25 | $85.1M | $194.8M | ||
| Q2 25 | $62.9M | $98.2M | ||
| Q1 25 | $24.0M | $178.2M | ||
| Q4 24 | $78.7M | $-205.8M | ||
| Q3 24 | $51.0M | $274.6M | ||
| Q2 24 | $43.4M | $216.5M |
| Q1 26 | — | — | ||
| Q4 25 | $50.2M | $68.5M | ||
| Q3 25 | $62.2M | $185.7M | ||
| Q2 25 | $47.8M | $91.8M | ||
| Q1 25 | $13.2M | $171.1M | ||
| Q4 24 | $68.3M | $-210.7M | ||
| Q3 24 | $32.8M | $270.2M | ||
| Q2 24 | $31.2M | $211.8M |
| Q1 26 | — | — | ||
| Q4 25 | 13.9% | 24.9% | ||
| Q3 25 | 17.4% | 67.9% | ||
| Q2 25 | 13.6% | 34.3% | ||
| Q1 25 | 4.2% | 64.5% | ||
| Q4 24 | 21.2% | -78.7% | ||
| Q3 24 | 10.3% | 103.3% | ||
| Q2 24 | 9.8% | 81.8% |
| Q1 26 | — | — | ||
| Q4 25 | 8.9% | 3.6% | ||
| Q3 25 | 6.4% | 3.3% | ||
| Q2 25 | 4.3% | 2.4% | ||
| Q1 25 | 3.4% | 2.7% | ||
| Q4 24 | 3.2% | 1.8% | ||
| Q3 24 | 5.7% | 1.7% | ||
| Q2 24 | 3.8% | 1.8% |
| Q1 26 | — | — | ||
| Q4 25 | 2.67× | 0.56× | ||
| Q3 25 | 3.18× | 1.42× | ||
| Q2 25 | 2.32× | 0.73× | ||
| Q1 25 | — | 1.37× | ||
| Q4 24 | 1.41× | -1.58× | ||
| Q3 24 | 1.55× | 2.16× | ||
| Q2 24 | 2.65× | 1.94× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
PB
| Net Interest Income | $321.1M | 87% |
| Noninterest Income | $46.5M | 13% |
